SEIKAGAKU CORPORATION
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.seikagaku.co.jp/
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Sodium Hyaluronate Injection
- Product Name
- 阿尔治
- Approval Number
- 国药准字HJ20140533
- Approval Date
- Mar 1, 2024
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Seikagaku Corporation
- Target Recruit Count
- 232
- Registration Number
- NCT05411367
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸Butchertown Clinical Trials, Louisville, Kentucky, United States
🇺🇸Andover Eye Associates, Inc., Andover, Massachusetts, United States
PK and Safety of SI-722 in IC/BPS
- Conditions
- Interstitial CystitisBladder Pain Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Seikagaku Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT04208087
- Locations
- 🇺🇸
American Institute of Research, Los Angeles, California, United States
🇺🇸TriValley Urology Medical Group, Murrieta, California, United States
🇺🇸Premier Medical Associates, The Villages, Florida, United States
SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Seikagaku Corporation
- Target Recruit Count
- 352
- Registration Number
- NCT03607838
- Locations
- 🇺🇸
Delta Clinical Research, Mobile, Alabama, United States
🇺🇸Pain Medicine Associates, Inc., Fountain Valley, California, United States
🇺🇸University of California San Diego - Center for Pain Medicine, La Jolla, California, United States
SI-613 Study for Knee Osteoarthritis
- Conditions
- Osteoarthritis, Knee
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Seikagaku Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT03209362
- Locations
- 🇺🇸
Tucson Orthopaedic Institute, Tucson, Arizona, United States
🇺🇸MM Medical Center, Inc., Miami, Florida, United States
🇺🇸Quality Research and Medical Center, LLC, Miami, Florida, United States
A Study of SI-6603 in Patients With Lumbar Disc Herniation
- Conditions
- Intervertebral Disc DiseaseLumbar Disc Disease
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Seikagaku Corporation
- Target Recruit Count
- 1011
- Registration Number
- NCT02421601
- Prev
- 1
- 2
- 3
- Next
News
Seikagaku Launches Phase III Trials for Single-Injection Osteoarthritis Treatment in Japan
Seikagaku Corporation has initiated three Phase III clinical studies in Japan for Gel-One®, evaluating its efficacy in both knee and hip osteoarthritis patients.
FDA Panel Supports Condoliase Injection for Herniated Disc-Related Leg Pain
FDA advisory panel voted 8-4 in favor of condoliase for radicular leg pain due to lumbar disc herniation, highlighting its potential for patients who have not responded to conservative treatments.
Condoliase (SI-6603) Shows Promise in Phase 3 Trials for Lumbar Disc Herniation
SI-6603, an investigational treatment, significantly improved leg pain compared to sham in U.S. and placebo in Japan at Week 13 in Phase 3 trials.